Blue Water Vaccines

Blue Water Vaccines, Inc. is a biotechnology company that focuses on the research and development of transformational vaccines to prevent infectious diseases worldwide. Its vaccine platform has molecular properties that enable delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. The company's influenza vaccine program uses proprietary technology to identify specific epitopes, or proteins, with cross-reactive properties that enable the potential development of a universal flu vaccine. Its pipeline includes novel vaccine candidates licensed from research institutions and seeks to develop vaccines that provide long-lasting immunity to harmful viral and bacterial pathogens that cause infections in patient populations with high unmet needs. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.

CINCINNATI, July 20, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that the Company has entered into a Sponsored Research Agreement (the “SRA”) with Cincinnati Children's Hospital Medical Center (“Cincinnati Children's”) to explore vaccine development of its norovirus shell and protrusion (S&P) platform for multiple diseases.

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with Cincinnati Children's Hospital Medical Center for S&P Vaccine Platform Development

CINCINNATI, June 06, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Joseph Hernandez, Chairman and Chief Executive Officer of BWV, will present at the JMP Securities Life Science Conference. Mr. Hernandez will present a corporate overview and update for BWV's vaccine candidate pipeline.

Blue Water Vaccines to Present at the JMP Securities Life Science Conference

CINCINNATI, May 19, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing vaccines, announces a collaboration with the multidisciplinary Center for R&D in Immunobiologics (“CeRDI”), an initiative of Instituto Butantan (“Butantan”). Through this partnership, Butantan, a leading Brazilian producer of immunobiologic products and vaccines, and BWV will develop the universal influenza vaccine candidate, BWV-101, in Brazil.

Blue Water Vaccines Announces Collaboration with Instituto Butantan for the Development of BWV-101, a Universal Influenza Vaccine Candidate

Blue Water Vaccines has a long road ahead of it. The company has multiple drug candidates in its pipeline but has not yet started clinical trials.

Blue Water Vaccines: Estimates And Expectations

CINCINNATI, May 13, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), today announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent business developments and progress. Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including influenza, norovirus, rotavirus, and acute otitis media (AOM) from Streptococcus pneumoniae colonization.

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer of Blue Water Vaccines, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand webcast viewing starting on Wednesday, May 25, 2022, at 9:00am EDT.

Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference

Carvana

Redbox Entertainment

Rocket Companies, Inc.

Unity Software

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring order to the markets.

5 Stocks Halted In Wednesday's Session: Here's Why

CINCINNATI, May 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today announced an expanded license agreement has been signed with St. Jude Children's Research Hospital (“St. Jude”). Through research funded by Blue Water Vaccines, St. Jude designed genetic constructs to express bacterial proteins on the surface of Streptococcus pneumoniae.

Blue Water Vaccines Announces Expanded License Agreement with St. Jude Children's Research Hospital for Novel Bacterial Vaccine Platform

Blue Water Vaccines turned heads as BWV stock shot up more than 90% with no apparent news. What's going on with BWV stock?

Why Is Blue Water Vaccines (BWV) Stock Up Today?

CINCINNATI, April 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), a biopharmaceutical company developing transformational vaccines, today issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission (“SEC”) on April 20, 2022, which included a presentation (the “WVC presentation”) delivered by the Company at the World Vaccine Congress 2022 in Washington, DC. This presentation by Brian Price, Ph.D., BWV's Head of Technology Strategy, shows identification of H3N2 and influenza B epitopes of limited variability discovered by scientists at The University of Oxford.

Blue Water Vaccines Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Proceeds To Fund Research and Development of BWV-101, BWV-102 and BWV-103 Proceeds To Fund Research and Development of BWV-101, BWV-102 and BWV-103

Blue Water Vaccines Announces Closing of $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103. Proceeds To Fund Research and Development of BWV-101, BWV 102 and BWV-103.

Blue Water Vaccines Announces $8 Million Private Placement Priced At-the-Market Under Nasdaq Rules

CINCINNATI, April 11, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Brian Price, Ph.D., Head of Technology Strategy, will deliver a presentation during the World Vaccine Congress 2022 in Washington, DC. BWV will present on its universal influenza vaccine candidate, which utilizes the exclusively licensed epitopes of limited variability identified by scientists at The University of Oxford.

Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022

CINCINNATI, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, today announced the closing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. The shares began trading on the Nasdaq Capital Market under the ticker symbol “BWV” on February 18, 2022.

Blue Water Vaccines Announces Closing of Initial Public Offering

CINCINNATI, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines, Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), a biopharmaceutical company developing vaccines, today announced the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “BWV” on February 18, 2022.

News for Blue Water Vaccines Stock (BWV)